Application Sponsors
ANDA 211360 | AUROBINDO PHARMA LTD | |
Marketing Status
Application Products
001 | TABLET, EXTENDED RELEASE;ORAL | 220MG;120MG | 0 | NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE | NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE |
FDA Submissions
UNKNOWN; | ORIG | 1 | AP | 2022-06-01 | STANDARD |
Submissions Property Types
CDER Filings
AUROBINDO PHARMA LTD
cder:Array
(
[0] => Array
(
[ApplNo] => 211360
[companyName] => AUROBINDO PHARMA LTD
[docInserts] => ["",""]
[products] => [{"drugName":"NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE","activeIngredients":"NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE","strength":"220MG;120MG","dosageForm":"TABLET, EXTENDED RELEASE;ORAL","marketingStatus":"Over-the-counter","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"06\/01\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2022-06-01
)
)